John Johnson

October 12, 2026

Axogen Receives New Analyst Coverage and Valuation Upside. Axogen has attracted new analyst coverage from Robinhood and B of A Securities, both issuing bullish notes and setting price targets around $52. A Yahoo analysis suggests the stock may be about 26% undervalued on cash‑flow grounds, while the company has fallen 22.6% in the past month. These developments highlight renewed investor interest and potential upside relative to recent price action.

October 17, 2026

Xeris Biopharma Highlights Endocrinology Data and Files KEYEVIS Lawsuit. Xeris Biopharma disclosed new data on its commercial portfolio and pipeline at several scientific meetings, emphasizing its role in the endocrinology market. The company also initiated patent infringement lawsuits in New Jersey federal court concerning its KEYEVIS product. These developments provide both scientific validation and legal exposure that may influence market perception.

September 25, 2026

Verastem presents ovarian cancer data at IGCS, outlines pipeline. Verastem Oncology reported a late‑breaking oral presentation of its RAMP 201 low‑grade serous ovarian cancer molecular profiling and tumor biomarker analysis at the IGCS 2026 Annual Global Meeting. The company also highlighted the launch of its ovarian cancer therapy and progress on the KRAS G12D program during an H.C. Wainwright event. These updates reflect ongoing clinical development and investor communication around its oncology pipeline.